ADVERTISEMENT
Podcasts
Non-Chemotherapy Approach Induces High Rate of Undetectable MRD in CLL
02/27/2020
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a trial exploring the combination of ibrutinib and venetoclax for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement